AKT1 and prostate carcinoma: We chose TrC1 prostate cancer cells as a model cell line without known genetic alterations in the PI3K/Akt pathway and thus normal endogenous Akt activity as well as Akt1−/− MEF cells without endogenous Akt1 or other alterations in the PI3K/Akt signalling that may influence the E17K effects.